RIDA®GENE MRSA is a multiplex real-time PCR for the direct, qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant coagulase-negative Staphylococci from human nasal or nasal/throat swabs, cultures, wound, axilla, groin and perineum swabs. RIDA®GENE MRSA multiplex real-time PCR is intended for use as an aid in diagnosis of MRSA infection.
Staphylococcus aureus is a major cause of nosocomial infections in hospitals and healthcare settings. Transmission occurs through health care providers or other patients. It is estimated that 30% of the healthy population are colonised (asymptomatic carriers) with S. aureus. Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of nosocomial infections worldwide (hospital- acquired MRSA also called HA-MRSA). Beside HA-MRSA infections also community-acquired MRSA infections (CA-MRSA) occur, which are acquired outside the hospital. MRSA are methicillin (oxacillin) resistant by virtue of the chromosomal mec A gene that encodes the penicillin binding protein (PBP2a). The mecA gene is located on a mobile genetic element called SCCmec gene cassette (Staphylococcal cassette chromosome mec). In contrast to infections with MSSA (Methicillin-sensible Staphylococcus aureus), MRSA infections are associated with a higher morbidity, mortality, long lasting hospitalization and higher healthcare costs. Risk factors for MRSA infection within healtcare settings include prolonged hospital stay, history of MRSA infection or colonisation, proximity to patients infected with MRSA and prolonged antibiotic treatment. In the European Union more than 150,000 hospital patients get infected with MRSA each year. An early, fast and systematic MRSA screening enables a specific treatment of infected patients and an introduction of appropriate hygiene interventions prevents a MRSA-transmission and spread. Conventional culture-based methods for detection of MRSA require 48 to 72 hours. Real-time PCR assays enable an early and rapid MRSA screening on the day of hospital admission as part of an infection prevention program.